AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10099039
Drug: 10.0 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg/d isradipine
Trial: 22315014
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss therapy
Trial: 20049572
Drug: Continuous intraarticular
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraarticular infusion with 300 mL ropivacaine 0.2% at a speed of 5 mL/hour
Trial: 20049572
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution at an infusion speed of 5 mL/hour (Control)
Trial: 12508961
Drug: Doxazosin (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2-4 mg/day)
Trial: 1659975
Drug: Temafloxacin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin (600 mg)
Trial: 6790805
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of nitroglycerin
Trial: 28742505
Drug: Hops dry
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hops dry extract (Melcalin hops); 0.2 gr capsules once daily for 4 weeks
Trial: 28742505
Drug: Placebo; 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; 0.2 gr capsules once daily for 4 weeks
Trial: 16680561
Drug: Desipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (50 mg) alone
Trial: 16680561
Drug: Desipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (50 mg) with cinacalcet (90 mg for 7 days)
Trial: 9440757
Drug: 5-FU continuous
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU continuous intravenous infusion (CI)
Trial: 9440757
Drug: 5-FU bolus
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU bolus administration
Trial: 7787380
Drug: Pre‐retirement programmes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐retirement programmes including transition and choice‐making skills; no specific dosage or duration mentioned.
Trial: 1969290
Drug: Fentanyl administered
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl administered i.v. before propofol infusion
Trial: 29909704
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution plus oral fluids
Trial: 29909704
Drug: Dextrose solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose solution 5% plus oral fluids
Trial: 29909704
Drug: Oral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluids alone
Trial: 24314359
Drug: TAK-085 2
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 2 g (2 g once daily)
Trial: 24314359
Drug: TAK-085 4
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 4 g (2 g twice daily)
Trial: 24314359
Drug: EPA-E 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-E 1.8 g (0.6 g three times daily)
Trial: 24314359
Drug: TAK-085 2
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 2 g
Trial: 24314359
Drug: TAK-085 4
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 4 g
Trial: 24314359
Drug: EPA-E 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-E 1.8 g
Trial: 17370494
Drug: O3 acupoint
RxNorm normalized name: O3-Methylmorphine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O3 acupoint injection (30 microg/mL)
Trial: 17370494
Drug: Danggui point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danggui point injection
Trial: 15049986
Drug: Doxazosin 1-8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 1-8 mg once daily
Trial: 15049986
Drug: Alfuzosin 5-10
RxNorm normalized name: alfuzosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 5-10 mg divided in two or three daily doses
Trial: 11269737
Drug: 5-FU (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (370 mg/m2 i.v. over 1 h, days 2-6)
Trial: 9517642
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg at night for 2 weeks
Trial: 2652864
Drug: Ketoconazole high
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole high dose (H.D.)
Trial: 195190
Drug: CL 88,277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CL 88,277 (250 mg, 1 ml administered three times a day plus one dose prior to challenge and for six consecutive post-challenge days)
Trial: 29749716
Drug: Test dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dalfampridine tablet (generic formulation)
Trial: 29749716
Drug: Branded dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded dalfampridine tablet (reference formulation)
Trial: 28829368
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of grape and apple polyphenols
Trial: 23780354
Drug: PC: positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC: positive control group (no medication)
Trial: 14975461
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of half-dose reteplase and abciximab
Trial: 11725230
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (lumbar fusion)
Trial: 11725230
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment (physical therapy)
Trial: 8204228
Drug: Chronic calcium
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic calcium channel blockers
Trial: 8204228
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium channel blockers
Trial: 3144169
Drug: Oral encainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral encainide (75 to 200 mg/day)
Trial: 3144169
Drug: Oral quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinidine (1,200 mg/day)
Trial: 28187222
Drug: 50 µg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/wk 25‐hydroxyvitamin‐D3
Trial: 28187222
Drug: 150 µg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg/wk vitamin D3
Trial: 28187222
Drug: Control cells
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cells (not specified dosage)
Trial: 23881439
Drug: Alendronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (35 mg/week) and calcium lactate (600 mg/day)
Trial: 23881439
Drug: Calcium lactate
RxNorm normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate (600 mg/day)
Trial: 19808656
Drug: Intravenous fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fructose (0.5 g/kg)
Trial: 19808656
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (0.5 g/kg)
Trial: 15799911
Drug: Amiodarone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone therapy for 3 months post-surgery
Trial: 11055218
Drug: Vitrectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrectomy with intravitreal administration of 0.4 mg gentamicin
Trial: 23377509
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA)
Trial: 12814846
Drug: Coping-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping-oriented therapy approach
Trial: 10227413
Drug: Regular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular administration of antihypertensive medication
Trial: 1909218
Drug: rt‐PA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA (100 mg over a 3‐hour period)
Trial: 30593884
Drug: Patient-completed Decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-completed Decision Support Tool (DST) for mental health care, including feedback on DST responses, treatment priorities, motivation assessment, and severity-matched treatment recommendations.
Trial: 22492501
Drug: synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: synthetic human PTH 1‐34 (hPTH 1‐34), injected two to three times daily for 18 months
Trial: 17202798
Drug: Propofol (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (induction 1.5 mg/kg, maintenance 1.5 mg kg(‐1) h(‐1))
Trial: 17202798
Drug: Midazolam (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (induction 0.5 mg/kg, maintenance 0.1 mg kg(‐1) h(‐1))
Trial: 10573224
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with dihaematoporphyrin ether and argon dye laser photoradiation
Trial: 6753120
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg daily
Trial: 28255849
Drug: Cladribine (CdA)
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine (CdA) as a single agent or in combination with interferon (IFN) β‐1a
Trial: 16913434
Drug: 5‐HT at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT at 1,000 micromol/L
Trial: 16913434
Drug: 5‐HT at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT at 0.1 micromol/L
Trial: 11132390
Drug: Mycobacterium vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium vaccae (0.1 mL)
Trial: 11132390
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 mL tetanus toxoid)
Trial: 9061219
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral prednisolone/day for 2 weeks
Trial: 9061219
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral prednisolone/day for 2 weeks
Trial: 9061219
Drug: 3.2 mg
RxNorm normalized name: menthol 3.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg inhaled budesonide/day for 2 weeks
Trial: 3535621
Drug: Phenylpropanolamine (Rinexin)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (Rinexin) 50 mg twice daily
Trial: 30218844
Drug: 3-month dual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor
Trial: 12665540
Drug: 80% theta(L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% theta(L)
Trial: 11013280
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days
Trial: 11013280
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (100 mg/m(2))
Trial: 8780837
Drug: Naltrexone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (1 mg/kg daily for 4 weeks)
Trial: 1622413
Drug: Methotrexate sodium
RxNorm normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered after an overnight fast
Trial: 1622413
Drug: Methotrexate sodium
RxNorm normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered within 10 minutes of consuming a high fat‐content breakfast
Trial: 6421561
Drug: New glibenclamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New glibenclamide preparation (Euglucon 5, HB 419)
Trial: 6421561
Drug: Conventional glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional glibenclamide preparation (Euglucon N, HB 420)
Trial: 29760159
Drug: MTX+ (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX+ (methotrexate therapy with hydroxychloroquine added if no remission)
Trial: 27896461
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block using 20 mL of 0.375% ropivacaine
Trial: 27896461
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group using 20 mL of 0.9% normal saline infusion
Trial: 24532502
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of dual antiplatelet therapy (DAPT) due to unexpected requests for non-cardiac surgery or invasive procedures
Trial: 24532502
Drug: Overall outcomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall outcomes related to DAPT discontinuation
Trial: 23731986
Drug: Irish set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irish set dancing classes once per week plus a weekly home program for 6 months
Trial: 15986752
Drug: Postoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotic therapy and late suture removal
Trial: 7482373
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (implied control)
Trial: 7125306
Drug: Fenoterol 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 5.0 mg
Trial: 7125306
Drug: Fenoterol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 7.5 mg
Trial: 7125306
Drug: Ephedrine 24
RxNorm normalized name: ephedrine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 24 mg
Trial: 29246256
Drug: Oral glycine
RxNorm normalized name: glycine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycine (0.5 g/kg/day, dissolved in any liquid)
Trial: 24825180
Drug: Long-term proton
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term proton pump inhibitor therapy (>1 year)
Trial: 17538639
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (TTG) 50 mg/day for 3 months
Trial: 17538639
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (TTG)
Trial: 15779317
Drug: Adper Prompt‐L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt‐L‐Pop (AP, 3M ESPE) on dentin
Trial: 15779317
Drug: Adper Prompt‐L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt‐L‐Pop (AP, 3M ESPE) on enamel
Trial: 11782694
Drug: Naftidrofuryl (Praxilene),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (Praxilene), 200 mg three times daily for 6 months
Trial: 9513821
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for gastro-oesophageal reflux
Trial: 9513821
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for non-ulcer dyspepsia with Helicobacter pylori eradication
Trial: 9513821
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for duodenal ulceration
Trial: 9513821
Drug: Prokinetic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic agent for non-ulcer dyspepsia
Trial: 8443719
Drug: Cysteine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine (200 mg orally four times a day)
Trial: 8443719
Drug: Methylmethionine sulfonium
RxNorm normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylmethionine sulfonium chloride (MMSC) (500 mg orally four times a day)
Trial: 3821139
Drug: Calea zacatechichi
RxNorm normalized name: Iresine calea extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calea zacatechichi extracts (low doses)
Trial: 30241722
Drug: Azithromycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (5 mg/kg per day for 21 days)
Trial: 30241722
Drug: Amoxicillin-clavulanate (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (22.5 mg/kg, twice daily for 21 days)
Trial: 27048694
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid 1g 10 min bolus followed by 1g 8h infusion
Trial: 24754183
Drug: Reinforcing kidney,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcing kidney, activating blood circulation and ovarian stimulation compound recipe (treatment group)
Trial: 18373490
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg once daily (q.d.)
Trial: 18373490
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily (b.i.d.)
Trial: 18373490
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg with a 200 mg redose (p.r.n.) on day 1
Trial: 7792793
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (K‐Can) 50 mg/day for 4 weeks
Trial: 7792793
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg for 4 weeks
Trial: 7792793
Drug: Furosemide 25
RxNorm normalized name: furosemide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 25 mg for 4 weeks
Trial: 7792793
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks before each treatment
Trial: 1673723
Drug: Astemizole (H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (H1 receptor blocker)
Trial: 31086126
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus administered via nasogastric tube on Day 1
Trial: 31086126
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus administered via nasogastric tube on Day 3
Trial: 27858183
Drug: THP (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THP (25 mg/m2 × 11)
Trial: 27858183
Drug: DNR (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNR (30 mg/m2 × 11)
Trial: 26109819
Drug: Recombinant streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant streptokinase (rSK) suppositories (200000 IU every 8 hours for the first 3 units, then every 12 hours until 8 administrations completed)
Trial: 26109819
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone acetate suppositories (25 mg every 8 hours up to a maximum of 24 administrations)
Trial: 26109819
Drug: Recombinant streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant streptokinase (rSK) suppositories (both schedules)
Trial: 26109819
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone acetate suppositories
Trial: 26109819
Drug: Recombinant streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant streptokinase (rSK) suppositories
Trial: 22987606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IPD and AD
Trial: 17535995
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 0.33 mg/kg body weight per week for a mean of 6.7 years
Trial: 15470332
Drug: SJW extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW extract with high HYF content (900 mg/d)
Trial: 15470332
Drug: SJW extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW extract with low HYF content (900 mg/d)
Trial: 7508396
Drug: 960 mg
RxNorm normalized name: glycerin 960 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg cotrimoxazole and 10 mg oxazepam (group B)